Form 4: Precision Biosciences Director Boosts Stake with Open Market Share Purchase

Melinda Brown, a Director at Precision Biosciences Inc., has increased her beneficial ownership in the company through an open market purchase of common stock.

Summary

• Melinda Brown, a Director of Precision Biosciences Inc. (DTIL), acquired 1,682 shares of common stock.
• The transaction occurred on June 25, 2025, at a weighted average price of $4.14 per share, with prices ranging from $4.14 to $4.15.
• Following this purchase, Ms. Brown's total beneficial ownership in Precision Biosciences common stock increased to 20,565 shares.
• The transaction was made pursuant to a Rule 10b5-1(c) plan, indicating a pre-arranged trading strategy.

Sentiment

Score: 7

Explanation: The sentiment is positive due to a director's open market purchase of company stock, signaling confidence. The score is not higher as it represents a single, relatively small transaction by one individual.

Positives

• The purchase by a company director signals confidence in the company's future prospects and valuation.
• The transaction was executed under a Rule 10b5-1 plan, which demonstrates a pre-planned and transparent approach to insider trading.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future outlook.

Industry Context

Insider purchases, such as this one by a director, are generally viewed by investors as a positive signal, indicating management's belief in the company's intrinsic value and future performance. In the biotechnology sector, where companies often have long development cycles and significant R&D expenses, such signals of confidence from insiders can be particularly impactful.

Corporate Governance

Related Party Transactions

• The acquisition of common stock by Director Melinda Brown is considered a related party transaction, as it involves a key management personnel and the company's securities.

Stakeholder Impact

• Shareholders: The insider purchase may instill greater confidence among existing and potential shareholders, potentially leading to positive sentiment and increased demand for the stock.
• Employees: While not directly impacted, a positive signal from a director can indirectly boost employee morale and confidence in the company's stability and future.

Key Dates

Recommendation

Keywords

Precision Biosciences, DTIL, Insider Trading, Director Stock Purchase, SEC Form 4, Equity Acquisition, Rule 10b5-1 Plan, Biotechnology, Gene Editing